Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer - a long-term observation.
Adult
Aged
Arm
Breast Neoplasms
/ radiotherapy
Cancer Survivors
Female
Humans
Incidence
Lymph Node Excision
/ adverse effects
Lymphedema
/ epidemiology
Mastectomy, Segmental
/ adverse effects
Middle Aged
Radiotherapy, Adjuvant
/ adverse effects
Retrospective Studies
Risk Factors
Surveys and Questionnaires
Axillary surgery
BCRL
Breast cancer
Breast-conserving surgery
Lymphedema
Quality of life
Radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
07 Mar 2019
07 Mar 2019
Historique:
received:
10
10
2018
accepted:
25
02
2019
entrez:
9
3
2019
pubmed:
9
3
2019
medline:
2
4
2019
Statut:
epublish
Résumé
Arm-lymphedema is a major complication after breast cancer. Recent studies demonstrate the validity of predicting Breast Cancer Related Lymphedema (BCRL) by self-reports. We aimed to investigate the rate of BCRL and its risk factors in the long-term using self-reported symptoms. Data was collected from 385 patients who underwent multimodal therapy for nodal positive breast cancer, including breast conserving surgery, axillary dissection, and local or locoregional radiotherapy. Two validated questionnaires were used for the survey of BCRL (i.e. LBCQ-D and SDBC-D). These were analysed collectively with retrospective data of our medical records. 23.5% (n = 43) suffered a permanent BCRL (stage II-III) after a median follow-up time of 10.1 years (4.9-15.9 years); further 11.5% (n = 23) reported at least one episode of reversible BCRL (Stage 0-I) during the follow-up time. 87.1% of the patients with lymphedema developed this condition in the first two years. Adjuvant chemotherapy was a significant risk factor for the appearance of BCRL (p = 0.001; 95%-CI 7.7-10.2). Breast cancer survivors face a high risk of BCRL, particularly if axillary dissection was carried out. Almost 90% of BCRL occurred during the first two years after radiotherapy. Self-report of symptoms seems to be a suitable instrument of early detection of BCRL.
Sections du résumé
BACKGROUND
BACKGROUND
Arm-lymphedema is a major complication after breast cancer. Recent studies demonstrate the validity of predicting Breast Cancer Related Lymphedema (BCRL) by self-reports. We aimed to investigate the rate of BCRL and its risk factors in the long-term using self-reported symptoms.
METHODS
METHODS
Data was collected from 385 patients who underwent multimodal therapy for nodal positive breast cancer, including breast conserving surgery, axillary dissection, and local or locoregional radiotherapy. Two validated questionnaires were used for the survey of BCRL (i.e. LBCQ-D and SDBC-D). These were analysed collectively with retrospective data of our medical records.
RESULTS
RESULTS
23.5% (n = 43) suffered a permanent BCRL (stage II-III) after a median follow-up time of 10.1 years (4.9-15.9 years); further 11.5% (n = 23) reported at least one episode of reversible BCRL (Stage 0-I) during the follow-up time. 87.1% of the patients with lymphedema developed this condition in the first two years. Adjuvant chemotherapy was a significant risk factor for the appearance of BCRL (p = 0.001; 95%-CI 7.7-10.2).
CONCLUSIONS
CONCLUSIONS
Breast cancer survivors face a high risk of BCRL, particularly if axillary dissection was carried out. Almost 90% of BCRL occurred during the first two years after radiotherapy. Self-report of symptoms seems to be a suitable instrument of early detection of BCRL.
Identifiants
pubmed: 30845971
doi: 10.1186/s13014-019-1243-y
pii: 10.1186/s13014-019-1243-y
pmc: PMC6407279
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Références
J Natl Cancer Inst. 2001 Jan 17;93(2):96-111
pubmed: 11208879
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1209-15
pubmed: 12654429
Nurs Res. 2003 Nov-Dec;52(6):370-9
pubmed: 14639083
J Clin Nurs. 2005 Aug;14(7):798-804
pubmed: 16000093
Breast Cancer Res Treat. 2006 Feb;95(3):279-93
pubmed: 16163445
Int Wound J. 2005 Mar;2(1):47-62
pubmed: 16722853
Surg Oncol. 2006 Nov;15(3):153-65
pubmed: 17187979
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):775-82
pubmed: 17416770
J Clin Oncol. 2008 Jul 20;26(21):3536-42
pubmed: 18640935
J Clin Oncol. 2009 Jan 20;27(3):390-7
pubmed: 19064976
Ann Surg Oncol. 2009 Jul;16(7):1959-72
pubmed: 19365624
Psychooncology. 2010 Mar;19(3):299-305
pubmed: 19399782
Lymphology. 2009 Dec;42(4):161-75
pubmed: 20218084
Lymphology. 2010 Sep;43(3):118-27
pubmed: 21226414
Ann Surg Oncol. 2012 Aug;19(8):2580-9
pubmed: 22395997
Breast. 2012 Jun;21(3):361-5
pubmed: 22460058
J Am Coll Surg. 2013 Mar;216(3):380-9; quiz 511-3
pubmed: 23266421
Lancet Oncol. 2013 May;14(6):500-15
pubmed: 23540561
Facts Views Vis Obgyn. 2013;5(2):106-15
pubmed: 24753936
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Strahlenther Onkol. 2016 Jan;192(1):8-16
pubmed: 26416291
Breast Cancer (Dove Med Press). 2015 Oct 15;7:345-52
pubmed: 26527899
N Engl J Med. 2015 Nov 5;373(19):1878-9
pubmed: 26535517
Cancer Res Treat. 2016 Oct;48(4):1330-1337
pubmed: 26875199
Breast Care (Basel). 2016 Feb;11(1):45-50
pubmed: 27051396
Breast. 2016 Aug;28:29-36
pubmed: 27183497
Radiother Oncol. 2016 Dec;121(3):348-356
pubmed: 27890425
Radiat Oncol. 2017 Jan 23;12(1):25
pubmed: 28114948
Strahlenther Onkol. 2017 Jul;193(7):543-551
pubmed: 28492995
Qual Life Res. 2017 Oct;26(10):2573-2592
pubmed: 28623442
JAMA Oncol. 2018 Feb 1;4(2):250-251
pubmed: 29242929
Breast Care (Basel). 2017 Dec;12(6):385-390
pubmed: 29456470
Lymphology. 2016 Dec;49(4):170-84
pubmed: 29908550
Cancer Nurs. 1995 Dec;18(6):467-71
pubmed: 8564943